First, we now have 2 approved bispecific antibodies+2 CAR-T therapies, all targeting BCMA. This is different than the time Blenrep was initially approved. Those BCMA based therapies are associated with higher ORR/PFS (though no direct comparison) ➡️https:
4,488 followers
3,422 followers
RT @HadidiSamer: Check out our review on Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives #mmsm…
4,488 followers
Check out our review on Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives #mmsm @UAMSMyeloma @uamscancer Free access👇 ➡️ https://t.co/EzKQ12dEd8 https://t.co/xZqzjOliv9